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Background: The aim of our study was to demonstrate the added value of routine transesophageal
echocardiography (TEE) for correctly positioning the transseptal system in the fossa ovalis (FO), thus
potentially preventing complications during ﬂuoroscopy-guided transseptal puncture (TP), and for
assessing the optimal puncture site within the FO according to the expected procedure type.
Methods: Ninety-one patients undergoing pulmonary vein isolation (PVI) procedures by cryoballoon
technique for drug-resistant paroxysmal or persistent atrial ﬁbrillation (AF) were prospectively included.
In 57 patients, the TP procedure was performed under ﬂuoroscopic guidance and septal localization was
conﬁrmed by contrast injection through the needle and demonstration of septal tenting in both the
anteroposterior and left lateral ﬂuoroscopic projections. In 34 patients, TP was performed under TEE
guidance and positioning was targeted to perform the TP procedure in the more anterior and inferior
locations of the FO. Two patient groups were compared according to the incidence of complications
directly attributable to transseptal catheterization, thromboembolic complications, recurrence rates after
the ablation procedure, total procedural time, and ﬂuoroscopy time.
Results: Fluoroscopy time (po0.001), total cryoablation time (p¼0.002), and total procedural time
(po0.001) were shorter in the TEE-guided group. Left inferior pulmonary vein (LIPV) cryoablation time
(p¼0.007) and right inferior pulmonary vein (RIPV) cryoablation time (p¼0.004) were signiﬁcantly
shorter and the number of applications to the LIPV (p¼0.007) and RIPV (p¼0.005) were signiﬁcantly
fewer in the TEE-guided group. Although there was a trend toward higher complication rates (20.6% vs.
31.6%, p¼0.37) and recurrence rates (11.8% vs. 20.1%, p¼0.26) in the ﬂuoroscopy-guided group, the
differences between the groups were not statistically signiﬁcant.
Conclusions: TEE-guided TP for AF ablation is associated with shorter ﬂuoroscopy time, shorter total
cryoablation time, and shorter total procedural time. Importantly, TEE-guided TP facilitates cryoablation
of the inferior pulmonary veins.
& 2016 Japanese Heart Rhythm Society. Published by Elsevier B.V. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Over the last decade, the unabated increase in the number of
transseptal catheterizations has been related to an increase in atrial
ﬁbrillation (AF) ablation procedures. Transseptal puncture (TP) is
usually safe in experienced hands [1,2]. However, it can be associated
with life-threatening complications [3,4]. Conventionally, the procedure
is performed under ﬂuoroscopic guidance and pressure monitoring. Toblished by Elsevier B.V. This is an
: þ90 2622334641.
,
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.com (K.S. Özcan),reduce the incidence of complications, TP can be performed under
transesophageal echocardiography (TEE) or intracardiac echocardio-
graphy (ICE) guidance [5,6]. The use of echocardiographic guidance for
TP allows direct visualization of the transseptal needle tip within the
fossa ovalis (FO), and thus, a safe TP in every patient. It is also impor-
tant to emphasize that the use of echocardiographic guidance enables
puncture site selection within the FO according to the expected pro-
cedure type (e.g., a more anterior puncture for ablation of an accessory
pathway at the mitral annulus or for ablation of ventricular tachycardia
vs. a lower and more posterior puncture for ablation of AF). Thus, the
puncture site location can make a signiﬁcant difference in mapping
and/or ablation catheter maneuverability. A neglected advantage of
echocardiographic guidance during TP is the possibility of initiating
anticoagulation safely before TP. This appears to be a very importantopen access article under the CC BY-NC-ND license
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sized that the use of echocardiographic monitoring during the entire
AF ablation procedure allows for additional beneﬁts beyond safe TP.
Echocardiographic monitoring throughout the ablation procedure may
help in understanding the real-time anatomy of relevant cardiac
structures such as the pulmonary veins, left atrial appendage, mitral
isthmus, cavotricuspid isthmus, etc.
To date, no randomized trial has compared the clinical out-
comes and success rates between TEE-guided and traditional
ﬂuoroscopic TP. Many studies conclude that cardiac imaging may
be better than ﬂuoroscopy for guiding TP [5,6] especially in less
experienced hands, but the advantages in routine use of imaging
modalities have not yet been demonstrated.2. Materials and methods
2.1. Patients
In this prospective observational study, we enrolled 91 con-
secutive patients who underwent pulmonary vein isolation (PVI) by
cryoballoon technique for documented AF between September 2012
and March 2014. All patients had symptomatic paroxysmal or per-
sistent AF and had failed Z1 antiarrhythmic drug(s) previously.
Patients who had AF episodes lasting 7 days were deﬁned as per-
sistent and those whose episodes self-terminated within 7 days
were deﬁned as paroxysmal AF [7].
Patients who had moderate-severe valvular disease, thrombus
in the left atrium (LA), TEE contraindications, uncontrolled thyroid
dysfunction, preprocedural signiﬁcant coronary artery stenosis,
anticoagulation contraindications, previous AF ablation, and LA
diameter 455 mm and patients who were pregnant were exclu-
ded from the study. A detailed medical history regarding AF and
related cardiovascular and/or systemic conditions was obtained
from all patients. The patients’ symptomatic severity was recorded
according to the European Heart Rhythm Association (EHRA)
score. CHA2DS2-VASc scores were calculated for each patient
based on relevant guidelines [7]. Informed consent was obtained
from each patient before enrollment. The study was conducted in
compliance with the principles outlined in the Declaration of
Helsinki and approved by the Institutional Ethics Committee.
2.2. Methods
All patients underwent standard transthoracic echocardio-
graphy to rule out structural abnormality and TEE to rule out
thrombus in the LA. In patients undergoing TEE, sedation was
achieved by 2.5 mg midazolam intravenous bolus dose. If neces-
sary, an additional 1 mg or a total maximum 8 mg dose at 5-min
intervals was administered intravenously. Antiarrhythmic drugs
were discontinued ﬁve half-lives before the procedure. Antic-
oagulation was stopped at least 48–72 h before the procedure. In
the patient group in whom the TP procedure was performed under
ﬂuoroscopic guidance, a 70 UI/kg heparin intravenous bolus was
administered after gaining LA access. In the other patient group in
whom the TP procedure was performed under TEE guidance, the
same heparin dose was administered at the beginning of the
procedure. In all patients, activated clotting time (ACT) 4250 s
was maintained during the procedure.
In both groups, all procedures were performed under conscious
sedation using midazolam boluses. In all patients, invasive arterial
blood pressure, oxygen saturation, and electrocardiogram (ECG)
were continuously monitored throughout the procedure.
For the TP procedure in the ﬂuoroscopic guidance group, the TP
sheath and dilator were advanced into the superior vena cava
(SVC) over a guidewire via the right femoral vein. After removingthe guidewire and aspirating and ﬂushing the dilator, a Brock-
enbrough needle (BRK-1, St. Jude Medical, Minnetonka, MN, USA)
was inserted in the dilator. Thereafter, the sheath/dilator/needle
assembly was slowly withdrawn while monitoring ﬂuoroscopy.
Under ﬂuoroscopic guidance (anteroposterior projection), during
gradual sheath/dilator/needle withdrawal oriented between the
3:30 and 5:30 handle position, the FO was engaged, indicated by a
sudden displacement of the sheath tip and/or septal tenting.
Septal localization was also conﬁrmed by contrast injection
through the needle and demonstration of septal tenting in both
the anteroposterior and left lateral ﬂuoroscopic projections.
In the TEE-guided group, the operator conﬁrmed that the
transseptal needle was in a correct position for TP with TEE gui-
dance. After appropriate positioning, TP was performed in the
more anterior and inferior locations of the FO. The TEE probe was
removed after successful TP.
In both groups, the sheath was then exchanged for a 12-Fr
steerable transseptal sheath (FlexCath, Medtronic CryoCath, Min-
neapolis, USA) over a guidewire (0.032-in., 180-cm Super Stiff, St.
Jude Medical, St. Paul, MN, USA). Baseline potentials of all PVs
were recorded with a lasso catheter (Biosense Webster, Inc., Dia-
mond Bar, CA, USA). Distal coronary sinus pacing was performed
to conﬁrm the presence of the left PV potentials. In all patients, a
28-mm cryoballoon catheter (Arctic Front, Medtronic CryoCath LP)
was used for PVI. The cryoballoon was maneuvered to all PV ostia
by means of the steerable 12-Fr sheath and a guidewire inserted
through the lumen of the balloon catheter. The balloon was
inﬂated in the LA and then directed toward the PV ostia. Assess-
ment of balloon occlusion was performed by injecting 50% diluted
contrast through the cryoballoon catheter’s central lumen. The
duration of each freezing cycle was 240 s. A minimum of two
consecutive freezing cycles was performed with excellent or good
occlusion for each targeted PV. The procedure systematically
began with the left superior PV, followed by the left inferior, right
superior, and right inferior PVs, respectively. The right phrenic
nerve was constantly paced from the SVC during freezing at the
right-sided PVs. Direct palpation of right hemidiaphragmatic
excursions was performed during phrenic nerve stimulation. At
the end of the procedure, PV conduction was re-evaluated with a
lasso catheter. Successful PVI was deﬁned as the elimination (or
dissociation) of all PV potentials.
The patients remained under continuous hemodynamic and
ECG monitoring for 24 h. Immediately after the procedure and
24 h following the procedure, transthoracic echocardiography was
performed to ascertain the absence of pericardial effusion. Oral
anticoagulation with warfarin was initiated 4–6 h after the pro-
cedure and concomitant enoxaparin 1 mg/kg was also adminis-
tered until the target international normalized ratio of 2.0–3.0 was
reached. The patients remained on the antiarrhythmic drug regi-
men that was prescribed before ablation for a period of 3 months
following the procedure. Thereafter, procedural outcomes were
assessed off of the antiarrhythmic drug regimen. Regular follow-
up visits including medical history, clinical evaluation, 12-lead
surface ECG, and 24-h Holter monitoring were conducted 3, 6, 9,
and 12 months after ablation and every 6 months thereafter or
earlier if symptoms consistent with recurrent AF developed. The
need for oral anticoagulation was also evaluated 3 months after
ablation, based on the CHA2DS2-VASc score [7].
Acute procedural success was deﬁned as electrical isolation of
all PVs. The ﬁrst 3 months after AF ablation were deﬁned as the
blanking period. AF recurrence was deﬁned as the detection of AF
(Z30 s duration when assessed with 24-h ECG monitoring) after
3 months following AF ablation [8]. The TP success rate was
evaluated in terms of number of puncture attempts to gain access
to the LA. Procedural time was quantiﬁed as the time from
catheter positioning in the SVC to time of LA access. Total
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tion of all PVs), number of cryoablation applications to each pul-
monary vein, and maximum temperature applied were all recor-
ded. Safety was evaluated in terms of complications (TP-related
mild pericardial effusion noted on echocardiogram, major sys-
temic arterial embolization, cardiac tamponade, accidental punc-
ture of the aortic root and right atrium, and TP-related cardiac
death). The data of patients with and without TEE were compared.
2.3. Statistical analysis
The data were analyzed using SPSS for Windows (version 15.0,
SPSS Inc., Chicago, IL, USA). Continuous data are presented as
mean7SD, and categorical data are summarized as frequencies
and percentages. Group percentages were compared with the use
of the χ2 test or Fisher’s exact test, as appropriate. Group means for
variables with normal and non-normal distributions were com-
pared with the Student’s t-test for independent groups and the
Mann–Whitney U, respectively. A p value o0.05 was considered
statistically signiﬁcant.3. Results
Clinical and echocardiographic data of the study population are
given in Table 1. The study population consisted of 91 sympto-
matic patients with AF. Mean ages of the patients in the TEE-
guided group (group 1) and ﬂuoroscopy-guided group (group 2)
were 55.579.8 years (16 men, 47%) and 55.0710.4 years (28 men,
49%), respectively. Twenty-ﬁve patients (73.5%) in the TEE-guided
group and 37 patients (64.9%) in the ﬂuoroscopy-guided group
presented with paroxysmal AF. The median durations of AF in the
TEE-guided group and ﬂuoroscopy-guided group were 3.5 (2.0–
4.25) years and 3.0 (2.0–5.0) years, respectively. The median LA
diameter was 40 (interquartile range (IQR): 37–43) mm in the TEE-
guided group and 41 (IQR: 38.0–45.5) mm in the ﬂuoroscopy-
guided group. The median left ventricular ejection fraction was
60% (IQR: 55–65) in the TEE-guided group and in the ﬂuoroscopy-
guided group, similarly. Other demographic characteristics were
similar between groups.
The cryoablation procedural details are illustrated in Table 2.
The median total procedural time was 68 (IQR: 64–74) min in the
TEE-guided group and 83 (IQR: 72–97) min in the ﬂuoroscopy-Table 1
Patient characteristics.
TEE-guided
group, N¼34
Fluoroscopy-guided
group, N¼57
p Value
Age, years (mean7SD) 55.579.8 (37–
72)
55.0710.4 (33–71) 0.82
Sex (male/female) 16/18 28/29 0.85
Hypertension, n (%) 15 (44.1) 25 (43.9) 0.98
Diabetes mellitus, n (%) 4 (11.8) 8 (14.0) 1
Coronary artery disease, n
(%)
4 (11.8) 5 (8.8) 0.72
Cerebrovascular accident, n
(%)
1 (2.9) 1 (1.8) 1
Lone atrial ﬁbrillation, n (%) 9 (26.5) 27 (47.4) 0.08
Paroxsymal atrial ﬁbrilla-
tion, n (%)
25 (73.5) 37 (64.9) 0.39
CHA2DS2-VASc score
(median)
1.5 (IQR: 0–2.0) 1.0 (IQR: 0–2.5) 0.68
Left ventricular ejection
fraction, % (median)
60 (IQR: 55–65) 60 (IQR: 55–65) 0.22
Atrial ﬁbrillation duration,
years (median)
3.5 (2.0–4.25) 3.0 (2.0–5.0) 0.92
Left atrium size, mm (PLAX) 40 (IQR: 37–43) 41 (IQR: 38.0–45.5) 0.19guided group (po0.001). The ﬂuoroscopy times in the TEE-guided
group and in group 2 were 14 (IQR: 13–15) min and 16 (IQR: 14–
22) min, respectively (po0.001). The median total cryoablation
times in the TEE-guided group and in group 2 were 32 (IQR: 32–
36) min and 36 (IQR: 33–39) min, respectively (p¼0.002). Acute
procedural success was 100% in both groups. The maximal tem-
peratures reached at each pulmonary vein were similar between
the two groups (Table 2). Comparison of cryoablation times for
each pulmonary vein showed shorter cryoablation times at the
inferior pulmonary veins (8 [IQR: 8–8] vs. 8 [IQR: 8–11], p¼0.007,
at left inferior pulmonary veins [LIPVs] and 8 [IQR: 8–8] vs. 8 [IQR:
8–13], p¼0.004, at right inferior pulmonary veins [RIPVs],
respectively). Upper pulmonary vein cryoablation times were
similar. The TEE-guided group was associated with a lower num-
ber of cryoenergy applications at the inferior pulmonary veins (2
[IQR: 2–2] vs. 2 [IQR: 2–3], p¼0.007, for LIPVs and 2 [IQR: 2–2] vs.
2 [IQR: 2–4], p¼0.005, for RIPVs, respectively). Other procedural
data as presented in Table 2 were similar among groups.
The TP-related complications are given in Table 3. Pericardial
effusion without tamponade was seen in 2 patients (5.9%) in the
TEE-guided TP group and 5 (8.8%) in the ﬂuoroscopy-guided
group. There was no pericardial tamponade in the TEE-guided
group and only one patient experienced tamponade in the
ﬂuoroscopy-guided group. One patient in the ﬂuoroscopy-guided
group had a transient ischemic attack (TIA) manifesting as right
limb weakness that completely resolved before discharge. Dia-
phragm paralysis was seen in 2 patients (5.9%) vs. 4 (7%) in the
TEE-guided group and ﬂuoroscopy-guided group, respectively.
Gastroparesis was seen in 3 patients in the ﬂuoroscopy-guided
group, whereas none of the patients in the TEE-guided group had
gastroparesis. Inguinal hematoma and/or pseudoaneurysm was
seen in 3 patients (8.8%) in the TEE-guided TP group and 4 (7.0%)
in the ﬂuoroscopy-guided group. None of the study patients
required emergent surgery. Total complications seen were 7
(20.6%) and 18 (31.6%) in the two groups. All complication para-
meters were similar between groups (Table 3).
Table 4 shows the procedural success and recurrence rates.
There was no statistical difference in these parameters between
groups.4. Discussion
Previous studies suggest indirectly that the use of echocardio-
graphy may increase procedural safety, but to date, there are no
data to prove this directly. We showed a similar trend in the
present study. However, because of the small size of our study
group, it was not possible to show a statistically signiﬁcant
reduction in complication rates by using TEE guidance during the
procedure. Conventionally, the procedure is performed under
ﬂuoroscopic guidance and pressure monitoring. In experienced
hands, various modiﬁcations of this method have a reasonable
safety proﬁle. However, serious complications such as cardiac
tamponade (1.31%) or aortic perforation can still occur and can
lead to death (0.15%) [3,4]. To reduce the incidence of such com-
plications, TP can be done under TEE or ICE guidance. TEE neces-
sitates a higher level of sedation and is often not tolerated well. ICE
requires additional expertize and remarkably increases procedural
cost. In our study, we used TEE as a guide because of the lower
procedural cost.
TEE guidance can also be helpful during pulmonary vein
cryoablation for AF. Kerut et al. [9] described their ﬁrst 20 cases of
cryoablation for AF using TEE and found TEE to have better overall
procedural imaging and monitoring for pericardial effusion or
thrombus formation. They found TEE monitoring to be helpful
with positioning for interatrial septum (IAS) puncture, catheter tip
Table 2
Procedure characteristics.
TEE-guided group, N¼34 Fluoroscopy-guided group, N¼57 p Value
Septal thickness, mm 1.8870.33 (1.0–2.5) 1.8670.34 (1.0–2.5) 0.68
Median transseptal puncture time, s 433 (IQR: 372–474) 421 (IQR: 322–579) 0.67
Number of transseptal punctures, n 1 (IQR: 1–1) 1 (IQR: 1–2) o0.001
Median total cryoablation time, min 32 (IQR: 32–36) 36 (IQR: 33–39) 0.002
Median total ﬂuoroscopy time, min 14 (IQR: 1 3–15) 16 (IQR: 14–22) o0.001
Median total procedure time, min 68 (IQR: 64–74) 83 (IQR: 72–97) o0.001
LSPV maximum temperature (°C) 50 (IQR: 48–52) 49 (IQR: 48–51) 0.35
LIPV maximum temperature (°C) 48 (IQR: 45–50) 47 (IQR: 44–49) 0.13
RSPV maximum temperature (°C) 51 (IQR: 50–56) 51 (IQR: 49–53) 0.11
RIPV maximum temperature (°C) 46 (IQR: 44–49) 45 (IQR: 41–48) 0.11
LSPV cryoablation time, min 8 (IQR: 8–8) 8 (IQR: 8–8) 0.69
LIPV cryoablation time, min 8 (IQR: 8–8) 8 (IQR: 8–11) 0.007
RSPV cryoablation time, min 8 (IQR: 8–8) 8 (IQR: 8–8) 0.77
RIPV cryoablation time, min 8 (IQR: 8–8) 8 (IQR: 8–13) 0.004
LSPV number of applications 2 (IQR: 2–2) 2 (IQR: 2–2) 0.75
LIPV number of applications 2 (IQR: 2–2) 2 (IQR: 2–3) 0.007
RSPV number of applications 2 (IQR: 2–2) 2 (IQR: 2–2) 0.72
RIPV number of applications 2 (IQR: 2–2) 2 (IQR: 2–4) 0.005
IQR: interquartile range; LCPV: left common pulmonary vein; LIPV: left inferior pulmonary vein; LSPV: left superior pulmonary vein; RCPV: right common pulmonary vein;
RIPV: right inferior pulmonary vein; RSPV: right superior pulmonary vein.
Table 3
Complications.
TEE-guided
group, N¼34
Fluoroscopy-guided
group, N¼57
p Value
Pericardial effusion without
tamponade, n (%)
2 (5.9) 5 (8.8) 0.71
Pericardial effusion with tam-
ponade, n (%)
0 (0.0) 1 (1.8) 1
Thromboembolic events, n (%) 0 (0.0) 1 (1.8) 1
Diaphragm paralysis, n (%) 2 (5.9) 4 (7.0) 1
Gastroparesis, n (%) 0 (0.0) 3 (5.3) 0.29
Inguinal hematoma and/or
pseudoaneurysm, n (%)
3 (8.8) 4 (7.0) 0.75
Emergent surgery, n (%) 0 (0.0) 0 (0.0) –
Total number of complications,
n (%)
7 (20.6) 18 (31.6) 0.37
Table 4
Recurrence and follow-up.
TEE-guided group,
N¼34
Fluoroscopy-guided
group, N¼57
p Value
Acute success, n
(%)
34 (100) 57 (100) –
Recurrence (after
3 months), n (%)
4 (11.8) 12 (21.1) 0.26
Recurrence time,
days, and
median
239 (IQR: 222–274) 243 (IQR: 213–286) 0.40
Follow up, days,
and median
239 (IQR: 222–274) 243 (IQR: 214–286) 0.89
IQR: interquartile range.
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balloon catheter into each PV, with proper positioning within each
PV oriﬁce and documentation of PV occlusion for the cryoballoon
procedure. Use of TEE monitoring resulted in a perceived reduc-
tion in radiopaque contrast agent use and ﬂuoroscopy time. In our
study, we aimed to demonstrate the added value of routine TEE
use for correctly positioning the transseptal system in the FO, thus
potentially preventing complications during ﬂuoroscopy-guided
TP, and for assessing the optimal puncture site within the FO
according to the expected procedure type. Although there was a
trend toward higher complication rates in the ﬂuoroscopy-guided
group, the differences between the groups were not statistically
signiﬁcant. This is probably because of lower complication rates in
both groups and the small study size. Kautzner et al. [10] reported
that a retrospective analysis of 1692 TP procedures guided by ICE
between 2006 and 2009 revealed no complications associated
with the puncture and they added that this provides indirect
evidence that the use of online imaging may increase procedural
safety, especially in anatomical variants of the intraatrial septum,
which make the procedure challenging. They also emphasized that
the use of echocardiographic guidance enables puncture site
selection within the FO according to the expected procedure type
(e.g., a more anterior puncture for ablation of an accessory path-
way at the mitral annulus or for ablation of ventricular tachycardia
and a lower and more posterior puncture for ablation of AF). They
stated that even 1-cm difference in the puncture site location canmake a signiﬁcant difference in mapping and ablation catheter
maneuverability, and this seems to be even more important when
using “one-size-ﬁts-all” devices such as a cryoballoon. In general, a
posterior crossing is optimal when targeting posterior LA struc-
tures (e.g., the pulmonary veins during AF ablation). For patients
undergoing AF ablation with either magnetic navigation or balloon
technologies, it may be more favorable to puncture the fossa in a
more anterior and inferior location. An anterior and inferior fossa
approach for balloon pulmonary vein ablation greatly facilitates
access to the right inferior pulmonary vein. Su et al. [11] also
recommended a low anterior TP that was near or on the limbus of
the septum to allow more space for the balloon to be rotated
posteriorly to the right inferior PV as well as mechanical advan-
tages while accessing the other PVs. They noted that without
sufﬁcient distance between the puncture site and the right inferior
PV, optimal balloon positioning and occlusion might be difﬁcult.
The authors also emphasized that a low puncture location
improved balloon contact with the inferior aspects of the PVs.
They highly recommended using ICE to improve the safety of
transseptal catheterization, and they reported that ICE would also
provide early detection of complications (e.g., catheter-related and
pericardial thrombus) in ablation cases. The authors concluded
that the location of transseptal access was best at the lower third
of the septum, and anterior reach at the plane of ICE, where the
mitral valve was in view and bending of the distal 15-cm portion
of the typical transseptal needle could improve transseptal needle
engagement with the anterior portion of the septum. In our study,
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related to the easy access to the pulmonary veins by using TEE
guidance. Importantly, TP facilitates cryoablation of the inferior
pulmonary veins. LIPV and RIPV cryoablation time was sig-
niﬁcantly shorter and the numbers of LIPV and RIPV applications
were signiﬁcantly fewer in the TEE-guided group.
An important advantage of echocardiographic guidance during
TP is the possibility of initiating anticoagulation safely before TP.
This appears to be a very important beneﬁt, especially in patients
with AF, in whom the risk of thrombus formation is high, despite
anticoagulation to ACT 4250 s. In one study, the incidence of
thrombosis was signiﬁcantly lower when heparin was given before
the ﬁrst or second TP compared with heparin administration after
the TP (3.1% vs. 9%, po0.001). A thrombus was observed on a
mapping or ablation catheter in 16 of 29 patients, and in the
remaining 13, it was detected in the left atrium or appendage.
Additionally, a thrombus aspiration was safely performed through
the sheath in 21 of 29 cases [12]. In our study, we also aimed to
evaluate the advantages of echocardiographic guidance during TP
by initiating anticoagulation safely before TP, but only one patient
in the ﬂuoroscopy-guided group experienced a thromboembolic
event, which was not statistically different from the TEE-
guided group.
Although in our study the TEE probe was removed after suc-
cessful TP, there are many other possible advantages of continuous
TEE usage during the cryoablation of AF. Siklódy et al. [13] studied
124 PVs in 30 patients. Under continuous TEE assessment, a
cryoballoon was placed in the antrum of each PV aiming for
complete PV occlusion as documented by color Doppler. They
reported that, compared to their previously published data [14],
times with the cryoballoon were shorter (including both ablation
time and mapping time after ablation), similar to previously
published cryoballoon data [15]. Fluoroscopy times were not
longer and tended to be shorter at the end of the study, as they
had advanced in their learning curve. They also noted that TEE
allowed them to observe some undescribed phenomena, as well as
to resolve them during the procedure. Whenever PV occlusion
cannot be achieved, particularly by complex anatomies such as
extremely oval PV or supplementary right-sided PVs, echocardio-
graphy precisely localized the site of leakage and permitted the
development of alternative strategies. In the last cases of their
series, oval PVs were successfully ablated by freezing the balloon
at the cranial part of the PV antrum, and then pulling it gently back
after approximately 45 s under attentive TEE supervision, aiming
to close the gap by slightly pulling the frozen PV balloon toward
the caudal aspect of the antrum. This maneuver could only be
echocardiographically documented, as contrast ﬂuid could not be
injected through the balloon once the temperature fell below 0 °C.
Whenever this last “pull-back” strategy was not feasible, the PV
antrum was ablated in 2 stages, sequentially aiming at the cranial
and the caudal aspects of the PV antrum. Supplementary right-
sided PVs were speciﬁcally targeted by selecting them with the
guidewire: this approach permitted the creation of more complete
overlapping lesions around the septal PVs, as it includes LA tissue
located between the superior and the inferior septal PV. Addi-
tionally, they reported that TEE also avoided inﬂating the balloon
across the interatrial septum while attempting to isolate a right
inferior PV. In the study of Siklody et al., all patients underwent a
computed tomography scan, 3D anatomical models of the LA were
reconstructed, and if all PVs presented a diameter o18 mm, the
PV isolation was performed using a 23-mm diameter cryoballoon.
If any PV was 418 mm, they chose a 28-mm balloon (Arctic Front,
Cryocath, Montreal, Quebec, Canada, 11-Fr shaft size) in order to
create wider lesions including part of the LA surrounding the PV.
The main observed complication was a transient phrenic nerve
paralysis. The ratio between the vein size and the balloon sizeseems to play a crucial role in the appearance of this complication
[15,16]. TEE has been reported as strongly correlated to magnetic
resonance (MR) angiography in assessing PV anatomy [17], and
Peyrol et al. [18] suggested that TEE was an easily available and
effective tool to select the cryoballoon size for PVI according to
evaluated PV diameters and anatomy. Instead of using MR angio-
graphy for evaluating the PV diameter and selecting the cryo-
balloon size, we think that it is reasonable to use TEE. This way,
continuous TEE usage can enable us to evaluate the size of right-
sided PVs before choosing the balloon size and a large balloon can
be preferred. Although cryoballoon positioning at the PV antrum
may be inﬂuenced not only by the TP site but also by the anato-
mical ﬁndings of both the left atrium and the PV antrum in each
case, TEE-guided TP can shorten ﬂuoroscopy, total cryoablation,
and total procedural times. Importantly, it can also facilitate
cryoablation of inferior pulmonary veins.
4.1. Study limitations
This study was conducted in a single center with a small
sample size. In addition, because the patients could not tolerate
continuous TEE guidance, we had to remove the TEE probe after
successful TP. For this reason, unfortunately, we do not have any
additional data showing that the puncture location facilitates
inferior PV isolation when using the cryoballoon.5. Conclusions
Despite its small size, our study showed that TEE-guided TP for
AF ablation was associated with shorter ﬂuoroscopy time, total
cryoablation time, and total procedural time. Importantly, TEE-
guided TP can facilitate cryoablation of the inferior pulmonary veins.Conﬂict of interest
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